Amiodarone Dosage Guidelines for Stable Ventricular Tachycardia

Introduction to Amiodarone Therapy

The American Academy of Family Physicians recommends an oral amiodarone dosage of 800 to 1,600 mg per day in divided doses until a total of 10 g has been given, followed by a maintenance dose of 200 to 400 mg per day for stable ventricular tachycardia (VT) patients 1, 2
For hemodynamically stable monomorphic VT requiring IV therapy, the American Heart Association suggests administering 150 mg over 10 minutes, which can be repeated if necessary, followed by a 1 mg/min infusion for 6 hours, then 0.5 mg/min infusion, with a total dose over 24 hours not exceeding 2.2 g 3, 4

IV amiodarone onset of antiarrhythmic effect occurs rapidly, typically in less than 30 minutes, according to the American Family Physician 1, 5
For patients transitioning from IV to oral therapy, the oral dosing should be based on duration of IV therapy:

Initial oral loading dose of 800-1,600 mg/day in divided doses is recommended to achieve therapeutic effect quickly, as stated by the American Family Physician 1, 2
Continue loading dose until a total cumulative dose of 10 g has been administered, then reduce to maintenance dose of 200-400 mg daily 1, 2

The most serious potential adverse effect is pulmonary toxicity, which presents as subacute cough and progressive dyspnea with interstitial infiltrates on chest radiographs, according to the American Family Physician 1, 5
Common adverse effects include bradycardia and QT prolongation, gastrointestinal upset and constipation, and rarely, torsades de pointes 1, 2, 4, 5
Frequency of adverse effects correlates with total amiodarone exposure (dosage and duration), so use the lowest effective dose possible, as recommended by the American Family Physician 1, 5

When using amiodarone for stable VT, close monitoring is essential due to its narrow therapeutic window and potential for serious adverse effects, according to the American Family Physician 1, 2
In patients with structural heart disease and life-threatening ventricular arrhythmias, implantable cardioverter-defibrillators (ICDs) should be considered as primary therapy, with amiodarone as an adjunct to reduce frequency of ICD shocks, as suggested by the American Family Physician 7

The European Heart Journal reports that hypotension is a potential side effect during the transition period, particularly in elderly patients 8
The European Heart Journal notes that thyroid dysfunction, including both hypo- and hyperthyroidism, is a potential long-term adverse effect of amiodarone therapy 8
The European Heart Journal also reports that skin discoloration is a potential long-term adverse effect of amiodarone therapy 8